Bank of America just raised its EUR/USD forecast
Karah Parschauer, Executive Vice President and Chief Legal Officer at Ultragenyx Pharmaceutical (TADAWUL:2070) Inc. (NASDAQ:RARE), recently sold shares of the company’s common stock, according to an SEC filing. On February 27, Parschauer sold a total of 2,990 shares in two separate transactions. The shares were sold at prices ranging from $42.75 to $42.93, resulting in a total transaction value of $128,223. The transaction occurred as the $3.89 billion market cap biotech company trades near its 52-week low of $37.02, despite showing strong revenue growth of 29% in the last twelve months.InvestingPro analysis suggests the stock may be undervalued at current levels, with additional insights available in the comprehensive Pro Research Report.
Following these transactions, Parschauer’s direct ownership of Ultragenyx stock stands at 54,991 shares. The filing also reported an acquisition of 14,494 restricted stock units (RSUs) on March 1, which were awarded under the company’s 2023 Incentive Plan. These RSUs were granted at no cost and are subject to vesting conditions over a four-year period. Additionally, Parschauer received stock options for 26,074 shares, exercisable at $42.92 per share, with a vesting schedule extending up to 2035. The company maintains a healthy liquidity position with a current ratio of 2.37, indicating strong ability to meet short-term obligations.
In other recent news, Ultragenyx Pharmaceutical Inc. reported fourth-quarter 2024 earnings that exceeded expectations, driven by strong sales from its Crysvita, Dojolvi, and Evkeeza product lines. Canaccord Genuity responded by raising its price target to $136 and maintaining a Buy rating, reflecting confidence in Ultragenyx’s growth prospects and upcoming product launches. Additionally, Goldman Sachs reiterated its Buy rating with a $78 target, noting that Ultragenyx’s quarterly revenue of $164.9 million surpassed both their own and Visible Alpha’s estimates.
H.C. Wainwright maintained its Buy rating and $95 target, highlighting the FDA’s acceptance of Ultragenyx’s Biologics License Application for UX111, a gene therapy for Sanfilippo syndrome type A, with a Priority Review status. Cantor Fitzgerald also reaffirmed its Overweight rating with a $118 target, emphasizing the potential of Ultragenyx’s gene therapy programs and the progress of its DTX301 program for OTC deficiency.
The company projects full-year 2025 revenue between $640 million and $670 million, aligning with new estimates from Goldman Sachs and Visible Alpha. Analysts have noted the significance of Ultragenyx’s pipeline, including the anticipated PDUFA decision for UX111 in the second half of 2025 and potential BLA filings for DTX401. These developments are viewed as critical milestones for Ultragenyx, with the potential for significant future growth and profitability.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.